Negotiating structural vulnerability following regulatory changes to a provincial methadone program in vancouver, canada: A qualitative study

Social Science and Medicine

Volumn 133, Issue , 2015, Pages 168-176

  McNeil, Ryan ^a,b   Kerr, Thomas ^a,c   Anderson, Solanna ^a   Maher, Lisa ^d   Keewatin, Chereece ^e   Milloy, M J ^a,c   Wood, Evan ^a,c   Small, Will ^a,b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e British Columbia Association of People on Methadone   (Canada)

Author keywords

Canada; Drug policy; Health policy; Incentives; Methadone maintenance treatment; Methadose *Drug treatment; Structural vulnerability

Indexed keywords

METHADONE; NARCOTIC ANALGESIC AGENT;

DRUG; HEALTH POLICY; QUALITATIVE ANALYSIS; REGULATORY FRAMEWORK;

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; DRUG PROGRAM; DRUG USE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HIGH RISK BEHAVIOR; HUMAN; INTRAVENOUS DRUG ABUSE; MAINTENANCE THERAPY; MALE; METHADONE TREATMENT; OBSERVATIONAL STUDY; OPIATE ADDICTION; PHARMACY; PROSPECTIVE STUDY; QUALITATIVE RESEARCH; WITHDRAWAL SYNDROME; BRITISH COLUMBIA; DRUG THERAPY; EPIDEMIOLOGY; GOVERNMENT REGULATION; HEALTH CARE DELIVERY; INTERPERSONAL COMMUNICATION; LEGISLATION AND JURISPRUDENCE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; PROCEDURES; PROGRAM EVALUATION; SUBSTANCE ABUSE; VULNERABLE POPULATION; YOUNG ADULT;

BRITISH COLUMBIA; CANADA; VANCOUVER [BRITISH COLUMBIA];

ADULT; ANALGESICS, OPIOID; BRITISH COLUMBIA; FEMALE; GOVERNMENT REGULATION; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; METHADONE; MIDDLE AGED; NEGOTIATING; OPIATE SUBSTITUTION TREATMENT; PROGRAM EVALUATION; PROSPECTIVE STUDIES; QUALITATIVE RESEARCH; SUBSTANCE ABUSE, INTRAVENOUS; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 84927564605     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2015.04.008     Document Type: Article

References (64)

1. Anstice S., Strike C.J., Brands B. Supervised methadone consumption: client issues and stigma. Subst. Use Misuse 2009, 44(6):794-808.
2. Bourgois P. Disciplining addictions: the bio-politics of methadone and heroin in the United States. Cult. Med. Psychiatry 2000, 24(2):165-195.
3. College of Pharmacists of British Columbia Incentives Prohibition Resolution 2014, College of Pharmacists of British Columbia, Vancouver, Canada.
4. College of Pharmacists of British Columbia Changes to Methadone Formula Coming Feb. 1, 2014 2014, Retrieved from:. http://www.newsroom.gov.bc.ca/2014/01/changes-to-methadone-formula-coming-feb-1-2014.html.
5. College of Pharmacists of British Columbia Methadose: An Important Update from the Methadone Maintenance Program 2014, Retrieved July 3, 2014, From:. http://www.cpsbc.ca/programs/bc-methadone-program/methadose.
6. College of Pharmacists of British Columbia Professional Practice Policy-71: Delivery of Methadone for Maintenance 2014, College of Pharmacists of British Columbia, Vancouver, Canada.
7. College of Physicians & Surgeons of British Columbia Methadone Maintenance Program: Clinical Practice Guideline 2014, College of Physicians and Surgeons of British Columbia, Vancouver, Canada.
8. Corbin J., Strauss A. Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory 2008, Sage.
9. Corsi K.F., Lehman W.K., Booth R.E. The effect of methadone maintenance on positive outcomes for opiate injection drug users. J.Subst. Abuse Treat. 2009, 37(2):120-126.
10. Creswell J.W., Miller D.L. Determining validity in qualitative inquiry. Theory Pract. 2000, 39(3):124-130.
11. DeFulio A., Silverman K. The use of incentives to reinforce medication adherence. Prev. Med. 2012, 55(0):S86-S94.
12. Degenhardt L., Mathers B.M., Wirtz A.L., et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. Int. J. Drug Policy 2014, 25(1):53-60.
13. Degenhardt L., Charlson F., Mathers B., et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 2014, 109(8):1320-1333.
14. Fischer B. Prescriptions, power and politics: the turbulent history of methadone maintenance in Canada. J.Public Health Policy 2000, I(2):187-210.
15. Fry C.L., Treloar C., Maher L. Ethical challenges and responses in harm reduction research: promoting applied communitarian ethics. Drug Alcohol Rev. 2005, 24(5):449-459.
16. Gibson D.R., Flynn N.M., McCarthy J.J. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 1999, 13(14):1807-1818.
17. Gourevitch M.N., Hartel D., Tenore P., et al. Three oral formulations of methadone: a clinical and pharmacodynamic comparison. J.Subst. Abuse Treat. 1999, 17(3):237-241.
18. Harbottle T. Palace of hell: two survivors of life in slumlord George Wolsey's Palace Hotel describe a regime of exploitation. Tyee August 24, 2011, Retrieved from:. http://thetyee.ca/News/2011/08/24/Palace-Of-Hell/.
19. Harris J., McElrath K. Methadone as social control: institutionalized stigma and the prospect of recovery. Qual. Health Res. 2012, 22(6):810-824.
20. Harris M., Rhodes T. Methadone diversion as a protective strategy: the harm reduction potential of 'generous constraints'. Int. J. Drug Policy 2013, 24(6):e43-e50.
21. Holmes S.M. Structural vulnerability and hierarchies of ethnicity and citizenship on the farm. Med. Anthropol. 2011, 30(4):425-449.
22. Holt M. Agency and dependency within treatment: drug treatment clients negotiating methadone and antidepressants. Soc. Sci. Med. 2007, 64(9):1937-1947.
23. Howlett K., Andreatta D. Rampant Canadian pharmacy fraud sign of broken system, expert says. Globe Mail December 23, 2013, Retrieved from:. http://www.theglobeandmail.com/life/health-and-fitness/health/rampant-canadian-pharmacy-fraud-sign-of-a-broken-system/article16087916/.
24. Jones C.M. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Drug Alcohol Depend. 2013, 132(1-2):95-100.
25. Lazaruck S. Doctors call methadone kickbacks a 'big problm'. Vanc. Prov. September 10, 2008.
26. Luce J., Strike C. A Cross-Canada Scan of Methadone Maintenance Treatment Policy Developments 2011, For the Controlled Drugs & Substances Act.
27. Lopez A.M., Bourgois P., Wenger L.D., Lorvick J., Martinez A.N., Kral A.H. Interdisciplinary mixed methods research with structurally vulnerable populations: case studies of injection drug users in San Francisco. Int. J. Drug Policy 2013, 24(2):101-109.
28. Mathers B.M., Degenhardt L., Phillips B., et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008, 372(9651):1733-1745.
29. Mathers B.M., Degenhardt L., Ali H., et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010, 375(9719):1014-1028.
30. McCance-Katz E.F., Sullivan L.E., Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am. J. Addict. 2010, 19(1):4-16.
31. McNeil R., Small W., Lampkin H., Shannon K., Kerr T. "People knew they could come here to get help": an ethnographic study of assisted injection practices at a peer-run 'unsanctioned' supervised drug consumption room in a Canadian setting. AIDS Behav. 2014, 18(3):473-485.
32. Nelson P.K., Mathers B.M., Cowie B., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378(9791):571-583.
33. Ning A.M. Games of truth: rethinking conformity and resistance in narratives of heroin recovery. Med. Anthropol. 2005, 24(4):349-382.
34. Nolan S., Dias Lima V., Fairbairn N., et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction 2014.
35. Nosyk B., Anis A.H. Medical profiteering: the economics of methadone dispensation. Cmaj 2009, 180(11):1093-1094.
36. Nosyk B., Marsh D.C., Sun H., Schechter M.T., Anis A.H. Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996-2006. J.Subst. Abuse Treat. 2010, 39(1):22-31.
37. Nosyk B., Marshall B.D., Fischer B., Montaner J.S., Wood E., Kerr T. Increases in the availability of prescribed opioids in a Canadian setting. Drug Alcohol Depend. 2012, 126(1-2):7-12.
38. Nosyk B., Anglin M.D., Brissette S., et al. Acall for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff. 2013, 32(8):1462-1469.
39. Oliver P., Keen J., Rowse G., Ewins E., Griffiths L., Mathers N. The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care-led methadone maintenance service. Addiction 2010, 105(4):732-739.
40. Ontario Ministry of Health and Longterm Care Methadose and the Policy for Methadone Maintenance Treatment Reimbursement Under the Ontario Drug Benefit Program 2014, Ontario Ministry of Health and Longterm Care, Toronto, Canada.
41. Quesada J., Hart L.K., Bourgois P. Structural vulnerability and health: Latino migrant Laborers in the United States. Med. Anthropol. 2011, 30(4):339-362.
42. Radcliffe P., Stevens A. Are drug treatment services only for 'thieving junkie scumbags'? Drug users and the management of stigmatised identities. Soc. Sci. Med. 2008, 67(7):1065-1073.
43. Reisinger H.S., Schwartz R.P., Mitchell S.G., et al. Premature discharge from methadone treatment: patient perspectives. J.Psychoact. Drugs 2009, 41(3):285-296.
44. Rhodes T., Singer M., Bourgois P., Friedman S.R., Strathdee S.A. The social structural production of HIV risk among injecting drug users. Soc. Sci. Med. 2005, 61(5):1026-1044.
45. Rhodes T., Wagner K., Strathdee S., et al. Structural Violence and Structural Vulnerability Within the Risk Environment: Theoretical and Methodological Perspectives for A social Epidemiology of HIV Risk Among Injection Drug Users and Sex Workers. Rethink. Soc. Epidemiol. 2012, 205-230. Springer, Netherlands. P. O'Campo, J.R. Dunn (Eds.).
46. Richardson L., Wood E., Montaner J., Kerr T. Addiction treatment-related employment barriers: the impact of methadone maintenance. J.Subst. Abuse Treat. 2012, 43(3):276-284.
47. Robinson M. Police warn drug users after theft of highly potent methadone. Vanc. Sun 2014, February 6.
48. Rosenblum D., Castrillo F.M., Bourgois P., et al. Urban segregation and the US heroin market: a quantitative model of anthropological hypotheses from an inner-city drug market. Int. J. Drug Policy 2014, 25(3):543-555.
49. Roux P., Carrieri M.P., Cohen J., et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin. Infect. Dis. 2009, 49(9):1433-1440.
50. Sharif B., Nosyk B., Sun H., Marsh D.C., Anis A. Changes in the characteristics and levels of comorbidity among new patients into methadone maintenance treatment program in British Columbia during its expansion period from 1998-2006. Subst. Use Misuse 2013, 48(8):671-682.
51. Silver J.S., Shaffer H.J. Change intolerance to shifts in methadone formulation: a preliminary investigation. J.Subst. Abuse Treat. 1996, 13(4):331-339.
52. Sinoski K., Fowlie J. Methadone users 'get pharmacy kickbacks'. Vanc. Sun 2008, September 9.
53. Steels M.D., Hamilton M., McLean P.C. The consequences of a change in formulation of methadone prescribed in a drug clinic. Br. J. Addict. 1992, 87(11):1549-1554.
54. Strathdee S.A., Patrick D.M., Currie S.L., et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997, 11:59-65.
55. Strike C.J., Urbanoski K., Fischer B., Marsh D.C., Millson M. Policy changes and the methadone maintenance treatment system for opioid dependence in Ontario, 1996 to 2001. J.Addict. Dis. 2005, 24(1):39-51.
56. Strike C., Millson M., Hopkins S., Smith C. What is low threshold methadone maintenance treatment?. Int. J. Drug Policy 2013, 24(6):e51-56.
57. Stuek W. BC methadone dose change brings risk of overdose. Globe Mail 2014, January 4.
58. Syvertsen J.L., Robertson A.M., Rolón M.L., Palinkas L.A., Martinez G., Rangel M.G., Strathdee S.A. "Eyes that don't see, heart that doesn't feel": Coping with sex work in intimate relationships and its implications for HIV/STI prevention. Soc. Sci. Med. 2013, 87:1-8.
59. Tempalski B., Pouget E.R., Cleland C.M., et al. Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007. PLoS One 2013, 8(6):e64789.
60. Uhlmann S., Milloy M.J., Kerr T., et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction 2010, 105(5):907-913.
61. Unick G., Rosenblum D., Mars S., Ciccarone D. The relationship between US heroin market dynamics and heroin-related overdose, 1992-2008. Addiction 2014.
62. United Nations Office on Drugs and Crime World Drug Report 2014, United Nations Publication, New York, NY.
63. White B., Dore G., Lloyd A., Rawlinson W., Maher L. Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study. Med. J. Aust. 2014, 201(6):326-329.
64. Wood E., Montaner J.S.G., Yip B., et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. Can. Med. Assoc. J. 2003, 169(7):656-661.